Total compensation over a year long trial could exceed $1,000 while receiving cutting edge medication worth significantly more
The EMA and FDA imposed a respective label (52, 53)
"Even in that population, retatrutide demonstrated nearly 21 percent average weight loss at the highest dose, which is remarkable." Retatrutide Also Delivered Significant Results for People With Severe Obesity and Heart Disease The other trial, TRIUMPH-3, included nearly 2,000 adults with severe obesity (defined as a BMI of 40 or higher) and cardiovascular disease
The hidden GLP-1 connection Here is something fascinating that most articles about this combination miss entirely
since no significant effects were found, these have not been reported further (see Additional file 1)
Shah, MD, can be reached at [email protected].